These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37805050)

  • 81. Overactive bladder medication: Anticholinergics versus mirabegron by specialty.
    Sripad AA; Raker CA; Sung VW
    Urologia; 2022 Nov; 89(4):511-516. PubMed ID: 35195050
    [TBL] [Abstract][Full Text] [Related]  

  • 82. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder.
    Lee LK; Goren A; Zou KH; Odell K; Russell D; Araiza AL; Luo X
    Int J Clin Pract; 2016 Jan; 70(1):66-81. PubMed ID: 26662296
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Persistence and compliance with medication management in the treatment of overactive bladder.
    Kim TH; Lee KS
    Investig Clin Urol; 2016 Mar; 57(2):84-93. PubMed ID: 26981589
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Overactive bladder medication prescription trends from 2014 to 2018.
    Sripad A; Raker C; Shireman T; Sung V
    Neurourol Urodyn; 2022 Mar; 41(3):806-812. PubMed ID: 35132687
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The Impact of an Overactive Bladder Care Pathway on Longitudinal Patient Management.
    Selle JM; Hanson KT; Habermann EB; Gebhart JB; Trabuco EC; Occhino JA; Young AD; Linder BJ
    Urogynecology (Phila); 2024 Mar; 30(3):330-336. PubMed ID: 38484250
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Relationships between overactive bladder and cerebral white matter hyperintensity in outpatients at a memory clinic.
    Komiya H; Umegaki H; Ogama N; Sakurai T; Kuzuya M
    Geriatr Gerontol Int; 2021 Nov; 21(11):996-1002. PubMed ID: 34545679
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
    Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
    Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Practice Patterns for Women With Overactive Bladder Syndrome: Time Between Medications and Third-Line Treatments.
    Kirby AC; Park S; Cook SB; Odem-Davis K; Gore JL; Wolff EM
    Female Pelvic Med Reconstr Surg; 2020 Jul; 26(7):431-436. PubMed ID: 32265405
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Association Between Urinary Tract Infection and Overactive Bladder Treatment.
    Liao KM; Lio KL; Chou YJ; Kuo CC; Chen CY
    Front Pharmacol; 2021; 12():803970. PubMed ID: 35145406
    [No Abstract]   [Full Text] [Related]  

  • 91. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program.
    Yu YF; Nichol MB; Yu AP; Ahn J
    Value Health; 2005; 8(4):495-505. PubMed ID: 16091027
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study.
    Sexton CC; Coyne KS; Thompson C; Bavendam T; Chen CI; Markland A
    J Am Geriatr Soc; 2011 Aug; 59(8):1465-70. PubMed ID: 21718275
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Predictive Factors of De Novo Overactive Bladder After Artificial Urinary Sphincter Implantation in Men With Postprostatectomy Incontinence.
    Ko KJ; Lee CU; Kim TH; Suh YS; Lee KS
    Urology; 2018 Mar; 113():215-219. PubMed ID: 29030076
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Prevalence and initial management of overactive bladder in France: A cross-sectional study].
    Cornu JN; Amarenco G; Bruyere F; Chartier-Kastler E; Fatton B; Grise P; Haab F; Bourouina R
    Prog Urol; 2016 Jun; 26(7):415-24. PubMed ID: 27108102
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The Relationship Between Anxiety and Overactive Bladder or Urinary Incontinence Symptoms in the Clinical Population.
    Lai HH; Rawal A; Shen B; Vetter J
    Urology; 2016 Dec; 98():50-57. PubMed ID: 27450939
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population.
    Johnson TM; Walker D; Lockefeer A; Jiang B; Nimke D; Lozano-Ortega G; Kimura T
    Neurourol Urodyn; 2022 Nov; 41(8):1872-1889. PubMed ID: 36098417
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The Role of Sarcopenia in Overactive Bladder in Adults in the United States: Retrospective Analysis of NHANES 2011-2018.
    Song W; Hu H; Ni J; Zhang H; Zhang Y; Zhang H; Wang K; Zhang H; Peng B
    J Nutr Health Aging; 2023; 27(9):734-740. PubMed ID: 37754213
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The impact of diabetes on overactive bladder presentations and associations with health-seeking behavior in China, South Korea, and Taiwan: Results from a cross-sectional, population-based study.
    Lee WC; Chow PM; Hsu CN; Chuang YC
    J Chin Med Assoc; 2024 Feb; 87(2):196-201. PubMed ID: 38132568
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
    Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
    Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study.
    Chuang YC; Liu SP; Lee KS; Liao L; Wang J; Yoo TK; Chu R; Sumarsono B
    Low Urin Tract Symptoms; 2019 Jan; 11(1):48-55. PubMed ID: 28967230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.